RYAN PATRICK NOLAN MD, MBA
Prescription History 1295354579
Ophthalmology - Ophthalmic Plastic and Reconstructive Surgery in Durham, NC
NPI Status: Active since April 16, 2020
Contact Information
2351 ERWIN RD
DURHAM, NC
ZIP 27705
Phone: (919) 684-4224
Fax: (919) 385-0526
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for RYAN PATRICK NOLAN MD, MBA, an active Ophthalmic Plastic and Reconstructive Surgery specialist practicing in Durham, NC. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 23 documented patient claims. Among these therapy options, the most frequently utilized medication is Lumigan, which accounts for 12 claims alone.
Dorzolamide-Timolol
Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Student in an Organized Health Care Education/Training ProgramProvider Avg Cost Per Claim
$21.95
State Avg Cost Per Claim
$30.91
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.
Lumigan
Generic Formulation: BimatoprostSpecialty: Student in an Organized Health Care Education/Training ProgramProvider Avg Cost Per Claim
$458.48
State Avg Cost Per Claim
$435.44
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like RYAN PATRICK NOLAN MD, MBA provides transparency into local medical care patterns within Durham, NC.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmic Plastic and Reconstructive Surgery** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
